Bridged cyclic pyrimidinone compounds, their preparation, composition and use
Bridged cyclic pyrimidinone compounds are developed as Lp-PLA2 inhibitors to address the limitations of current treatments for neurodegenerative and cardiovascular diseases by targeting oxidative stress and neuroinflammation, offering a promising therapeutic option.
Patent Information
- Application Number
- JP2022569274
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-07-20
- Filing Date
- 2021-05-12
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-05-12
AI Technical Summary
Current treatments for neurodegenerative diseases such as Alzheimer's disease, glaucoma, and age-related macular degeneration, as well as cardiovascular diseases like atherosclerosis, are inadequate due to their focus on targeting Aβ amyloidosis and tau, which have shown limited clinical efficacy, and there is a need to explore other neuropathological mechanisms such as oxidative stress and neuroinflammation.
Development of bridged cyclic pyrimidinone compounds that act as novel Lp-PLA2 inhibitors to target the enzyme lipoprotein-associated phospholipase A2, which is implicated in these diseases, thereby reducing oxidative stress and neuroinflammation.
The bridged cyclic pyrimidinone compounds effectively inhibit Lp-PLA2, potentially providing a new therapeutic approach for treating neurodegenerative diseases and cardiovascular diseases by mitigating oxidative stress and neuroinflammation.
Smart Images

Figure 0007595964000001 
Figure 0007595964000002 
Figure 0007595964000003
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of medicine, and more particularly relates to a bridged cyclic pyrimidinone compound, or its tautomer, meso isomer, racemate, diastereoisomer, enantioisomer, or mixture thereof, its preparation method, its composition, and its use in medicine.In particular, the present specification relates to a bridged cyclic pyrimidinone derivative represented by general formula (I), its preparation method, and a pharmaceutical composition containing this derivative, and its use as an LpPLA2 inhibitor in the treatment of neurodegenerative diseases such as Alzheimer's disease, glaucoma, and age-related macular degeneration (AMD), or atherosclerosis and diabetic macular edema. [Background technology]
[0002] Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 superfamily (Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Chem Rev. 2011, 111, 6130-6185). It is secreted primarily by monocytes, macrophages, T lymphocytes, and chief cells (Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. J Biol Chem. 1990, 265: 9682-9687; Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M, Nojima S Kudo IJ Biol Chem. 1997, 272, 19708-19713). Phosphatidylcholine sn-2 esters are produced during the oxidation of low-density lipoprotein (LDL), and Lp-PLA2 hydrolyzes oxidized and modified phosphatidylcholine sn-2 esters to produce oxidized fatty acids and lysophosphatidylcholine (LysoPC) (Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Atherosclerosis. 2000, 150, 413-419; MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Biochem J. 1999, 338, 479-487). Both oxidized fatty acids and LysoPC act in activating macrophages, increasing oxidative stress, affecting T lymphocyte function, and inducing inflammatory responses (Quinn MT, Parthasarathy S, Steinberg D. Proc Natl Acad Sci US A. 1988, 85, 2805-2809). LysoPC reportedly induces the release of multiple cytotoxic inflammatory cytokines (Shi, et al, Atherosclerosis, 2007, 191, 54-62).LysoPC has also been implicated in leukocyte activation, induction of apoptosis, and mediation of endothelial dysfunction (Wilensky et al, Current Opinion in Lipidology, 2009, 20, 415-420).
[0003] Literature reports indicate that plasma Lp-PLA2 levels are associated with cardiovascular disease (Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C. Atherosclerosis. 2014, 235, 384-391), diabetic macular edema (DME) (Staurenghi G, Ye L, Magee MH, Danis RP, Wurzelmann J, Adamson P, McLaughlin MM, Darapladib DMESG. Ophthalmology. 2015, 122, 990-996), and prostate cancer (Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, Halgunset J. Clin Cancer Res. 2012, 18, 3261-3269).
[0004] Alzheimer's disease (AD) is a chronic neurodegenerative disorder that can lead to cognitive decline, emotional instability, irreversible memory loss, impaired navigation, speech impairment, and loss of self-protection (Hardy J, et al. Science 2002, 297, 353-356.). Alzheimer's disease usually worsens slowly over time and is the cause of 60%-70% of dementia cases, affecting about 6% of the population over 65 years of age. AD patients gradually withdraw from their families and society, become increasingly dependent on others for help, and ultimately progress to death. AD is one of the most costly diseases to treat in developed countries and is also expensive in other countries. These costs are expected to increase rapidly, especially as aging becomes a major social issue. Of course, AD is a complex, multifactorial disease. Although the pathogenesis of AD has not yet been fully elucidated, it is clear that several factors, including aggregated tau protein and Aβ peptides, oxidative stress, and neuroinflammation, are involved in the onset and progression of the disease (Echeverria V, Yarkov A, Aliev G. Prog Neurobiol. 2016, 144, 142-157). Current AD drug research and development is mainly focused on targeting Aβ amyloidosis and tau (Chiang K, Koo EH. Annu Rev Pharmacol Toxicol. 2014, 54, 381-405; Awasthi M, Singh S, Pandey VP, Dwivedi UN. J Neurol Sci. 2016, 361, 256-271). However, although preclinical data are strong, late-stage clinical trial results have yet to prove clinical efficacy. These disappointing results may suggest that treatments for AD need to explore other neuropathological mechanisms, such as oxidative stress and neuroinflammation.
[0005] Elevated plasma Lp-PLA2 levels are associated with increased risk of developing dementia, including AD (Van Oijen, et al. Annals of Neurology, 2006, 59, 139), and AD patients have been found to have vascular and mixed dementia, as well as high oxidized LDL levels (Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A, Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2015, 1, 131-140; Kassner et al. Current Alzheimer Research, 2008, 5, 358-366; Dildar, et al., Alzheimer Dis Assoc Disord, 24, April-June (2010); Sinem, et al. Current Alzheimer Research, 2010, 7, 463-469). Neuroinflammation and elevated levels of several inflammatory cytokines have also been found in AD patients (Colangelo, et al., Journal of Neuroscience Research, 2002, 70, 462-473; Wyss-Coray, Nature Medicine, 2006, 12, Sept.).
[0006] Based on all these findings, Lp-PLA2 is a potential target for treating AD, and this is also supported by the clinical results of the Lp-PLA2 inhibitor Rilapladib in AD patients (Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A, Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2015, 1, 131-140).
[0007] Glaucoma and age-related macular degeneration (AMD) are retinal neurodegenerative diseases. Buschini et al. have reported that inflammation, including TNF-α signaling, may play an important role in the pathogenesis of glaucoma and AMD (Buschini et al, Progress in Neurobiology, 2011, 95, 14-25; Tezel, Progress in Brain Research, vol. 173, ISSN 0079-6123, Chapter 28). Shi et al. have demonstrated that Lp-PLA2 inhibitors can block the release of inflammatory cytokines (Shi, et al, Atherosclerosis, 2007, 191, 54-62). Inhibition of Lp-PLA2 is a potential treatment for glaucoma and AMD.
[0008] The Lp-PLA2 complex is a β-chain (Tew DG, Boyd HF, Ashman S, Theobald C, Leach CA.Biochemistry.1998,37,10087-10093) and a β-chain (Jeong TS, Kim MJ, Yu H, Kim HS, Choi JK, Kim SS, Lee WS.Bioorg Med Chem Lett.2005,15,1525-1527;Jeong HJ,Park YD,Park HY,Jeong IY,Jeong TS,Lee WS.Bioorg Med Chem Lett.2006,16,5576-5579) with skeletal muscle (Lin EC,Hu Y,Amantea CM,Pham LM,Cajica J,Okerberg E,Brown HE,Fraser A,Du L,Kohno Y,Ishiyama J,Kozarich JW,Shreder KR.Bioorg Med Chem Lett.2012,22,868-871;Hu Y,Lin EC,Pham LM,Cajica J,Amantea CM,Okerberg E,Brown HE,Fraser A,Du L,Kohno Y,Ishiyama J,Kozarich JW,Shreder KR.Bioorg Med Chem Lett.2013,23,1553-1556.) (Nagano JM,Hsu KL,Whitby LR,Niphakis MJ,Speers AE,Brown SJ,Spicer T,Fernandez-Vega V,Ferguson J,Hodder P,Srinivasan P,Gonzalez TD,Rosen H,Bahnson BJ,Cravatt BF.Bioorg Med Chem Lett.2013,23,839-843).
[0009] For example, the Lp-PLA2 switch is Darapladib The smooth-running effect of the DME on the manufacturer (Magrioti V,Kokotos G.Expert Opin Ther Pat.2013;23:333-344). Summary of the Invention
[0010] The present inventors have found that Lp-PLA2 inhibitors play an important role in the treatment of neurodegenerative diseases, such as Alzheimer's disease (AD), glaucoma, and age-related macular degeneration (AMD), or cardiovascular diseases, including atherosclerosis, etc. Based on this, the present inventors have undertaken the development of novel Lp-PLA2 inhibitors, bridged cyclic pyrimidinone compounds.
[0011] The bridged cyclic pyrimidinone compound is a compound having a structure represented by formula (I) or a pharma- ceutically acceptable salt thereof. [ka] (I) During the ceremony, n 1 , n 2 , n 3 are each independently 0, 1 or 2; R 1 , R 2 are each independently selected from -H, a hydroxyl group, a cyano group, a halogen, an alkyl group, a deuterated alkyl group, a deuterated alkoxy group, a hydroxyalkyl group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, an alkoxy group, an arylene group, or a heteroarylene group; X 1 , X 2 are each independently selected from an alkylene group, -O-, -S-, or -NR'-; R' is selected from -H, an alkyl group, a deuterated alkyl group, or a cycloalkyl group; Ar is an arylene group or a heteroarylene group, in which a hydrogen atom is optionally substituted with one or more substituents, each of which is independently selected from a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a deuterated alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, an amino group substituted with a monoalkyl or dialkyl group, a nitro group, a carboxyl group, an aldehyde group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; Y is -H, a halogen, an alkyl group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, an alkoxy group, a deuterated alkyl group, a deuterated alkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an arylene group, a heteroarylene group, -OAr', -SAr', -NR''-Ar', -NR''R'', or -R'''-Ar'; Ar' is selected from an aryl group or a heteroaryl group, and a hydrogen atom in the aryl group or heteroaryl group may be substituted with one or more substituents, each of which is independently selected from a halogen, an alkyl group, a haloalkyl group, an alkoxy group, a hydroxyl group, a hydroxyalkyl group, a haloalkoxy group, a deuterated alkyl group, a deuterated alkoxy group, a cyano group, an amino group, a nitro group, a carboxyl group, an aldehyde group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R″ is H, an alkyl group, or a cycloalkyl group; R''' is an alkylene group; Z is O or S.
[0012] Preferably, the halogen atoms contained in the "halogen", "haloalkyl group", and "haloalkoxy group" are each independently selected from F, Cl, Br, or I; The alkyl groups contained in the above "alkyl group", "deuterated alkyl group", "deuterated alkoxy group", "hydroxyalkyl group", "haloalkyl group", "haloalkoxy group", "alkoxy group", and "amino group substituted with monoalkyl group or dialkyl group" are each independently C 1 -C 10 may be a linear or branched alkyl group; 1 -C 7 may be a linear or branched alkyl group; 1 -C 4 It may be a straight-chain or branched-chain alkyl group, and examples thereof include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-butyl group, an s-butyl group, an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, an isopentyl group, a 1-ethylpropyl group, a neopentyl group, an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylpentyl group, an isohexyl group, and a 1,1-dimethylbutyl group. , 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl; The "alkylene groups" each independently represent C 1 -C 10 may be a linear or branched alkylene group of the formula C 1 -C 7 may be a linear or branched alkylene group, C 1 -C 5It may be a linear or branched alkylene group, and examples thereof include a methylene group, an ethylene group, an n-propylene group, an isopropylene group, an n-butylene group, an isobutylene group, a t-butylene group, an s-butylene group, an n-pentylene group, a 1-methylbutylene group, a 2-methylbutylene group, a 3-methylbutylene group, an isopentylene group, a 1-ethylpropylene group, a neopentylene group, an n-hexylene group, a 1-methylpentylene group, a 2-methylpentylene group, a 3-methylpentylene group, an isohexylene group, a 1,1-dimethylbutylene group, a the alkyl group may be selected from the group consisting of ethylene, 2,2-dimethylbutylene, 3,3-dimethylbutylene, 1,2-dimethylbutylene, 1,3-dimethylbutylene, 2,3-dimethylbutylene, 2-ethylbutylene, n-heptylene, 2-methylhexylene, 3-methylhexylene, 2,2-dimethylpentylene, 3,3-dimethylpentylene, 2,3-dimethylpentylene, 2,4-dimethylpentylene, 3-ethylpentylene, and 2,2,3-trimethylbutylene; The "cycloalkyl group" is C 3 -C 10 may be a monocyclic or bicyclic cycloalkyl group, C 3 -C 7 may be a monocyclic cycloalkyl group, such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, or a cycloheptyl group; The "heterocyclyl group" may be a 3- to 10-membered non-aromatic heterocycle having one, two or three heteroatoms selected from N, O and S on the ring, the heterocycle may be a 3- to 10-membered non-aromatic ring having one or two heteroatoms selected from N and O on the ring, the heterocycle may be a 3- to 6-membered non-aromatic ring having one or two heteroatoms selected from N and O on the ring, the heterocycle may be a 3- to 10-membered non-aromatic ring having one or two heteroatoms selected from N and S on the ring, the heterocycle may be a 3- to 6-membered non-aromatic ring having one or two heteroatoms selected from N and S on the ring, The "aryl group" may be a 6- to 10-membered aryl, and may be selected from a phenyl group or a naphthyl group, and may be selected from a phenyl group, a 1-naphthyl group, or a 2-naphthyl group; The "arylene group" may be a 6- to 10-membered arylene group, and may be selected from a phenylene group or a naphthylene group; The "heteroaryl group" may be a 5- to 10-membered heteroaromatic ring having 1 to 3 heteroatoms selected from N, O, and S on the ring, or a 5- to 10-membered heteroaromatic ring having 1 to 2 heteroatoms selected from N, O, and S on the ring, the heteroaromatic ring may be selected from a pyridine ring, a pyrrole ring, a pyrazole ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a thiophene ring, and a furan ring, and the heteroaryl group may be a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, a pyridazin-3-yl group, a pyridazin-4-yl group, a pyridazin-4-yl group, a pyridazin-5-yl group, a pyridazin-6-yl group, a pyridazin-7-yl group, a pyridazin-8-yl group, a pyridazin-9-yl group, a pyridazin-10-yl group, a pyridazin-11-yl group, a pyridazin-12-yl group, a pyridazin-13-yl group, a pyridazin-14-yl group, a pyridazin-15-yl group, a pyridazin-16-yl group, a pyridazin-17-yl group, a pyridazin-18-yl group, a pyridazin-19-yl group, a pyridazin-20-yl group, a pyridazin-21-yl group, a pyridazin-22-yl group, a pyridazin-23-yl group, a pyridazin-24-yl group, a pyridazin-25-yl group, a pyridazin-26-yl group, a pyridazin-27-yl group, a pyridazin-28-yl group, a pyridazin-29-yl group, a pyridaz pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, quinolizidinyl, quinolyl, isoquinolyl, cinnolyl, phthalazinyl, naphthyridinyl, quinazolyl, quinoxalinyl, thieno[2,3-b]furyl, furo[3,2-b]pyranyl, pyrido[2,3-d]oxazinyl, pyrazolo[4,3-d]oxazolyl, imidazo[4,5-d]thiazolyl group, pyrazino[2,3-d]pyridazinyl group, imidazo[2,1-b]thiazolyl group, imidazo[1,2-b][l,2,4]triazinyl group, benzothienyl group, benzoxazolyl group, benzimidazolyl group, benzothiazolyl group, benzooxygenyl group, benzoxazinyl group, benzofuryl group, benzotriazolyl group, pyrrolo[2,3-b]pyridyl group, pyrrolo[3,2-c]pyridyl group, pyrrolo[3,2-b]pyridyl group, imidazo[4,5-b]pyridyl group, imidazo[4,5-c]pyridyl group, pyrazolo[4,3-d]pyridyl group, Pyrazolo[4,3-c]pyridyl, pyrazolo[3,4-c]pyridyl, pyrazolo[3,4-d]pyridyl, pyrazolo[3,4-b]pyridyl, imidazo[1,2-a]pyridyl, pyrazolo[1,5-a]pyridyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidyl, pyrido[3,2-d]pyrimidyl, pyrido[4,3-d]pyrimidyl, pyrido[3,4-d]pyrimidyl, pyrido[2,3-d]pyrimidyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,a pyrimido[4,5-d]pyrimidyl group, a pyrazolo[2,3-b]pyrazinyl group, or a pyrimido[4,5-d]pyrimidyl group, or a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, a pyrimidin-2-yl group, a pyrimidin-4-yl group, or a pyrimidin-5-yl group, The "heteroarylene group" may be a 5- to 10-membered ylidene heteroaromatic ring having 1 to 3 heteroatoms selected from N, O, and S on the ring, or a 5- to 10-membered ylidene heteroaromatic ring having 1 to 2 heteroatoms selected from N, O, and S on the ring, and the ylidene heteroaromatic ring may be selected from a pyridylidene ring, a pyrrolidylidene ring, a pyrazodylidene ring, a pyrimidylidene ring, a pyrazylidene ring, a pyridazylidene ring, a thienylidene ring, or a frylidene ring.
[0013] Preferably, the compound represented by formula (I) is in the form of its tautomer, meso isomer, racemate, diastereoisomer, enantioisomer, or a mixture of these isomers.
[0014] Preferably, n 1 , n 2 , n 3 are each independently 0, 1 or 2.
[0015] Preferably, n 1 is 1.
[0016] Preferably, n 2 is 1.
[0017] Preferably, n 3 is 1.
[0018] Preferably, R 1 , R 2 are each independently -H, fluorine, chlorine, bromine, iodine, a hydroxyl group, a hydroxyalkyl group, a cyano group, or C 1 -C 7Alkyl groups (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, s-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, or 2,2,3-trimethylbutyl group), C 1 -C 3 Deuterated alkyl groups (e.g., -CD 3 , -C 2 D 5 , or -C 3 D 7 ), C 1 -C 3 Deuterated alkoxy groups (e.g., -OCD 3 , -OC 2 D 5 , or -OC 3 D 7 ), C 1 -C 3 Haloalkyl groups (e.g., -CF 3 , -CHF 2 , -CH 2 F, -C 2 F 5 , -C 3 F 7 ), C 1 -C 7 Haloalkoxy group, C 1 -C 7 alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; R 1 may be -H, R 2 may be -H; X 1 , X 2are each independently 1 -C 7 an alkylene group, -O-, -S-, or -NR'-; X 1 is C 1 -C 7 Alkylene group (-CH 2 -, ethylene, n-propylene, isopropylene, n-butylene, or isobutylene, -O-, or -S-; X 1 is C 1 -C 7 X may be an alkylene group or -O-; 1 -CH 2 - or -O-, X 2 may be -O- or -S-; X 2 may be -O-, R' is -H, C 1 -C 7 Alkyl groups (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, s-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, butyl group, 3,3-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, or 2,2,3-trimethylbutyl group), deuterated alkyl group (-CD 3 , -C 2 D 5 , or -C 3 D 7 ), or C 3 -C 6 cycloalkyl groups (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups); Ar may be a phenylene or pyridyl group, and the hydrogen atoms in the phenylene or pyridyl group may be substituted with one, two or three substituents, each of which is independently selected from F, Cl, Br, I, -CN, -Me, -CF 3 , -CHF 2 , -C 2 H 5 , -C 3 H 7 , cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, -CD 3 , -OCD 3 , -OMe, -OCF 3 , or -OCHF 2 is selected from Ar may be an arylene group, Ar may be a phenylene group, and a hydrogen atom in the phenylene group may be substituted with one or two substituents, and the substituents are halogen, and the substituents may be F; Y is -H, -F, -Cl, -Br, -I, methyl group, ethyl group, n-propyl group, isopropyl group, -CD 3 , -OCD 3 , -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -OCF 3 , -OCHF 2 , -OCH 2 F, cyclopropyl, -cyclobutyl, -cyclopentyl, cyclohexyl, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 or -OAr', Y can be H, halogen, or -OAr'; Y can be H, -F, or -OAr'; Ar' may be selected from a phenyl group, a pyridyl group, a pyrimidyl group, a thienyl group, a pyrrolyl group, a pyrazolyl group, or a quinolyl group, and the hydrogen atoms in the ring of the phenyl group, the pyridyl group, the pyrimidyl group, the thienyl group, the pyrrolyl group, the pyrazolyl group, or the quinolyl group may each be independently replaced by one, two or three substituents, each of which is independently selected from F, Cl, Br, -CN, C 1 -C 7 Alkyl groups (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, s-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethyl butyl group, 3,3-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, or 2,2,3-trimethylbutyl group), -CD 3 , -OCD 3 , C 1 -C 6 Haloalkyl groups, -OCH 3 , -OC 2 H 7 , -OC 3 H 7 , C 1 -C 6 A haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, or C 3 -C 6 cycloalkyl groups (which may be selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups); Ar' may be selected from a phenyl group, a pyridin-3-yl group, a pyridin-4-yl group, or a pyrimidin-5-yl group, and said Ar' may be substituted with one or two substituents selected from a halogen, an alkyl group, a haloalkyl group, or a haloalkoxy group, and said substituents may be selected from F, Cl, -CH 3 , -CF 3 Or -OCF 3 may be selected from Z may be O or S; Z may be O.
[0019] Preferably, in the compound of formula (I) or a pharma- ceutically acceptable salt thereof, the compound of formula (I) is selected from the following compounds: [ka] [ka] Preferably, the pharma- ceutically acceptable salt comprises an anionic or cationic salt of a compound of formula (I), The pharma- ceutically acceptable salts may include alkali metal salts, alkaline earth metal salts, or ammonium salts of the compounds of formula (I); preferably, the alkali metals include sodium, potassium, lithium, or cesium, and the alkaline earth metals include magnesium, calcium, or strontium; The pharma- ceutically acceptable salt may include a salt formed between a compound of formula (I) and an organic base, The organic base may comprise a trialkylamine, pyridine, quinoline, piperidine, imidazole, methylpyridine, dimethylaminopyridine, dimethylaniline, N-alkylmorpholine, 1,5-diazabicyclo[4.3.0]nonene-5, 1,8-diazabicyclo[5.4.0]undecene-7, 1,4-diazabicyclo[2.2.2]octane; the trialkylamine may comprise trimethylamine, triethylamine, or N-ethyldiisopropylamine; and the N-alkylmorpholine may comprise N-methylmorpholine; The pharma- ceutically acceptable salt may include a salt formed between a compound of formula (I) and an acid, The acid may include an inorganic acid or an organic acid, the inorganic acid may include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, or carbonic acid, and the organic acid may include formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, glutamic acid, or pamoic acid.
[0020] In another aspect, there is provided a method for preparing a compound of formula (I) or a pharma- ceutically acceptable salt thereof, comprising the step of reacting a compound of formula (II) with a compound of formula (III) to produce a compound of formula (I), [ka] The process may comprise reacting a compound of formula (IV) with phosphorus oxychloride to produce a compound of formula (II), [ka] The process may include a step of cyclizing a compound of formula (V) to produce a compound of formula (IV), [ka] The method may include a step of reacting a compound of formula (VII) with a compound of formula (VIII) to produce a compound of formula (VI), and further removing protective groups from the compound of formula (VI) to produce a compound of formula (V), [ka] The preparation method may include the following reaction route: [ka] In each formula of the above production method, n 1 , n 2, n 3 , R 1 , R 2 , X 1 , X 2 , Z, Ar and Y are as defined above.
[0021] The specific reaction conditions for each of the above reactions are not particularly limited, and conventional reaction conditions or steps may be used.
[0022] In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective dose of one or more compounds of formula (I) as defined above or a pharma- ceutically acceptable salt thereof, and optionally pharma- ceutically acceptable adjuvants.
[0023] Preferably, the dosage form of the pharmaceutical composition comprises an oral formulation, a rectal formulation, or a parenteral formulation; The oral formulation may comprise a solid formulation or a liquid formulation, The solid formulation may comprise a tablet, a powder, a granule, or a capsule; The liquid formulation may include an aqueous or oily suspension, or a syrup; Preparations for parenteral administration may include injectable solutions or aqueous or oily suspensions.
[0024] In another aspect, there is provided use of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition, for the manufacture of an Lp-PLA2 inhibitor.
[0025] In another aspect, there is provided a use of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition, for the manufacture of a medicament for treating a neurodegeneration-related disease, comprising: The neurodegeneration-related disease may include Alzheimer's disease (AD), glaucoma, and age-related macular degeneration (AMD).
[0026] In another aspect, there is provided a use of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition, for the manufacture of a medicament for treating cardiovascular disease, diabetic macular edema (DME), or prostate disease, comprising: The cardiovascular disease may include atherosclerosis.
[0027] Beneficial Effects: The compound of formula (I) or a pharma- ceutical acceptable salt thereof is a bridged cyclic pyrimidinone compound and a novel Lp-PLA2 inhibitor, which can be used to treat neurodegenerative diseases, such as Alzheimer's disease (AD), glaucoma, and age-related macular degeneration (AMD), cardiovascular diseases including atherosclerosis, diabetic macular edema (DME), and prostate diseases. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present invention will now be further described with reference to the following examples, which should be understood as being merely illustrative of the present invention and are not intended to be limiting of the present invention.
[0029] The starting materials of the present invention may be synthesized by adopting or following methods well known in the art, or may be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc.), and Darui Chemicals.
[0030] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0031] Unless otherwise specified in the examples, the reaction temperature is room temperature, for example, 20°C to 30°C.
[0032] Example 1 Preparation of Compound 1 [ka] [ka] Step 1: Preparation of compound 1c [ka] At room temperature, 6-chlorouracil 1b (8.5 g, 58.0 mmol), tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 1a (15 g, 69.6 mmol), and triphenylphosphine (22.8 g, 86.9 mmol) were dissolved in a mixed solvent of 250 mL of anhydrous tetrahydrofuran and 25 mL of anhydrous N,N-dimethylformamide, and the solution was stirred at 0° C. under nitrogen protection in a flask containing diisopropyl azodicarboxylate (23 ml, 115.8 mmol). After stirring at 0°C for 2 hours, the mixture was allowed to react at room temperature overnight. The reaction solution was filtered, extracted with ethyl acetate (50mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified using silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain a colorless oily product 1c (8.34g, yield: 41.8%).
[0033] Steps 2 and 3: Preparation of compound 1e [ka] At room temperature, compound 3-(((6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)piperidine-1-carboxylate t-butyl 1c (8.34g, 24.3mmol) was dissolved in 80mL of dichloromethane, and 20mL of trifluoroacetic acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours to react, and the reaction solution was concentrated under reduced pressure, and the next reaction was carried out directly. The crude product of the previous step was dissolved in 100mL of acetonitrile, and diisopropylethylamine (9.3g, 72.9mmol) was added at room temperature, and the mixture was stirred for 4 hours to react, and the mixture was concentrated under reduced pressure, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 1e (4.7g, 93.3%).
[0034] 1H NMR(400MHz,DMSO)δ 11.01(s,1H),5.09(s,1H),3.84(m,1H),3.51(m,1H),3.30(m,1H),3.16(m,1H),3.04 (m,1H),2.94(m,1H),2.25(m,1H),1.89-1.68(m,2H),1.61-1.46(m,1H),1.36(m,1H).
[0035] Step 4: Preparation of compound 1f [ka] Compound 1e (2.0 g, 9.7 mmol) and dimethylaniline (2.34 g, 19.3 mmol) were dissolved in toluene at room temperature, and phosphorus oxychloride (1.48 g, 9.7 mmol) was added dropwise. The mixture was heated under reflux for 4 hours, and then the reaction was stopped with ice water. The mixture was concentrated under reduced pressure, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain white solid product 1f (0.89 g, 40.7%).
[0036] 1 H NMR (400 MHz, CDCl 3 )δ 6.06(s,1H),4.06(m,1H),3.77(m,1H),3.52(m,1H),3.29(m,1H),3.22-3. 15(m,1H),3.02(m,1H),2.52(m,1H),2.01-1.85(m,2H),1.62-1.44(m,2H).
[0037] Step 5: Preparation of Compound 1 [ka] (3-Fluorophenyl)methanol 1g (30mg, 0.24mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18mg, 0.44mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes to react. Compound 1f (50mg, 0.22mmol) was then added, and the mixture was stirred for 1 hour to react. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 1 (8mg, 11.5%).
[0038] 1 H NMR (400 MHz, CDCl 3 )δ 7.32(m,1H),7.15(m,2H),7.04-6.97(m,1H),5.60(s,1H),5.40(s,2H),4.06(m,1H),3.80(m,1H),3.44( m,1H),3.29-3.19(m,1H),3.13(m,1H),3.03(m,1H),2.41(m,1H),2.00-1.82(m,2H),1.58-1.45(m,2H).
[0039] Example 2 Preparation of Compound 2 [ka] (2,4-difluorophenyl)methanol (35 mg, 0.24 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 2 (10 mg, 13.6%).
[0040] 1 H NMR (400 MHz, CDCl 3)δ 7.49(m,1H),6.94-6.80(m,2H),5.58(s,1H),5.44(s,2H),4.09(m,1H),3.82(m,1H),3.45(m,1H), 3.29-3.20(m,1H),3.16(m,1H),3.05(mm,1H),2.44(m,1H),2.02-1.83(m,2H),1.57-1.47(m,2H).
[0041] Example 3 Preparation of Compound 3 [ka] (2,4,5-trifluorophenyl)methanol (39 mg, 0.24 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 3 (12 mg, 15.5%).
[0042] 1 H NMR (400 MHz, CDCl 3 )δ 7.32(m,1H),6.93(m,1H),5.57(s,1H),5.40(s,2H),4.06(m,1H),3.79(m,1H),3.43(m,1H),3. 28-3.21(m,1H),3.13(m,1H),3.02(m,1H),2.42(m,1H),1.93(m,2H),1.50(m,2H).MS(ESI):m / z 352.1[M+H] + .
[0043] Example 4 Preparation of Compound 4 [ka] (3,5-difluorophenyl)methanol (35mg, 0.24mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18mg, 0.44mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 1f (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 4 (6mg, 8.2%).
[0044] 1 H NMR (400 MHz, CDCl 3 )δ 6.99-6.93(m,2H),6.81-6.72(m,1H),5.63(s,1H),5.41(s,2H),4.09(m,1H),3.82(m,1H),3.53- 3.43(m,1H),3.33-3.20(m,1H),3.17(m,1H),3.06(m,1H),2.45(m,1H),1.96(m,2H),1.54(m,2H).
[0045] Example 5 Preparation of Compound 5 [ka] [ka] Step 1: Preparation of compound 5c
[0046] At room temperature, 2-(trifluoromethyl)pyridin-4-ol 5b (0.85 g, 5.2 mmol), 3,4,5-trifluorobenzaldehyde 5a (1 g, 6.2 mmol) and potassium carbonate (0.93 g, 6.76 mmol) were dissolved in 30 mL N,N-dimethylformamide, and stirred at 90 ° C for 1 hour to react. After cooling to room temperature, 100 mL of ice water was poured in, and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 5 / 1) to obtain a yellow solid product 5c (1.47 g, yield: 93.2%).
[0047] 1 H NMR (400 MHz, CDCl 3 )δ 9.97(s,1H),8.65(m,1H),7.63(m,2H),7.27(m,1H),7.01(m,1H).
[0048] Step 2: Preparation of compound 5d
[0049] 3,5-Difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde 5c (1.47 g, 4.85 mmol) was dissolved in 50 mL of ethanol at room temperature and added to NaBH 4 (184 mg, 4.85 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 2 / 1) to obtain white solid product 5d (1.04 g, yield: 70.3%).
[0050] 1 H NMR (400 MHz, CDCl 3)δ 8.59(m,1H),7.24(m,1H),7.11(m,2H),6.99(m,1H),4.75(m,2H),2.19(m,1H).
[0051] Step 3: Preparation of compound 5
[0052] (3,5-difluoro-4-((2-(trifluoromethylpyridin-4-yl)oxy)phenyl)methanol 5d (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes to react. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour to react. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 5 (13 mg, 12%).
[0053] 1 H NMR (400 MHz, CDCl 3 )δ 8.60(m,1H),7.26(s,1H),7.15(m,2H),6.99(m,1H),5.64(s,1H),5.43(s,2H),4.08(m,1H),3.80(m,1H), 3.47(m,1H),3.27(m,1H),3.16(m,1H),3.04(m,1H),2.44(m,1H),1.91(m,2H),1.53(m,2H).MS(ESI):m / z 494.9[M+H] + .
[0054] Example 6 Preparation of Compound 6 [ka] [ka] Step 1: Preparation of compound 6b
[0055] At room temperature, 2-methylpyridin-4-ol 6a (0.5 g, 4.6 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.88 g, 5.5 mmol) and potassium carbonate (0.823 g, 5.95 mmol) were dissolved in 30 mL N,N-dimethylformamide, and stirred at 90 ° C for 2 hours to react. After cooling to room temperature, 100 mL of ice water was poured in, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 6b (0.4 g, yield: 34.9%).
[0056] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(s,1H),8.39(m,1H),7.62-7.56(m,2H),6.70-6.66(m,2H),2.52(s,3H).
[0057] Step 2: Preparation of compound 6c
[0058] 3,5-Difluoro-4-((2-methylpyridin-4-yl)oxy)benzaldehyde 6b (0.4 g, 1.6 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (71 mg, 1.86 mmol) was added, and the reaction was stirred at room temperature for 0.5 hours, concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate (100 mL × 2). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the drying agent was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 6c (0.40 g, yield: 99%).
[0059] 1 H NMR (400 MHz, CDCl 3)δ 8.29(m,1H),7.07(m,2H),6.70-6.64(m,2H),4.73(s,2H),3.20(m,1H),2.50(s,3H).
[0060] Step 3: Preparation of compound 6
[0061] (3,5-difluoro-4-((2-methyl)pyridin-4-yl)oxy)phenyl)methanol 6c (55mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18mg, 0.44mmol) was added at 0°C, and the mixture was stirred at room temperature for 5 minutes, and then compound 1f (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid target product 6 (8mg, 8.2%).
[0062] 1 H NMR (400 MHz, CDCl 3 )δ 8.36(m,1H),7.10(m,2H),6.70-6.66(m,2H),5.63(s,1H),5.42(s,2H),4.08(m,1H),3.81(m,1H),3.47(m,1H), 3.30-3.22(m,1H),3.16(m,1H),3.05(m,1H),2.51(s,3H),2.44(m,1H),1.91(m,2H),1.53(m,2H).MS(ESI):m / z 441.0[M+H] + .
[0063] Example 7 Preparation of Compound 7 [ka] [ka] Step 1: Preparation of compound 7b
[0064] At room temperature, 6-methylpyridin-3-ol 7a (0.57 g, 5.2 mmol), 3,4,5-trifluorobenzaldehyde 5a (1 g, 6.2 mmol) and potassium carbonate (0.93 g, 6.76 mmol) were dissolved in 30 mL N,N-dimethylformamide, and stirred at 90 ° C for 1 hour. After cooling to room temperature, 100 mL of ice water was poured in, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 7b (0.91 g, yield: 69.2%).
[0065] 1 H NMR (400 MHz, CDCl 3 )δ 9.92(s,1H),8.28(s,1H),7.62-7.49(m,2H),7.18-7.10(m,2H),2.54(s,3H).
[0066] Step 2: Preparation of compound 7c
[0067] 3,5-Difluoro-4-((6-methylpyridin-3-yl)oxy)benzaldehyde 7b (0.91 g, 3.6 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (161 mg, 4.3 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 7c (0.89 g, yield: 98.4%).
[0068] 1 H NMR (400 MHz, CDCl 3)δ 8.20(m,1H),7.16-6.98(m,4H),4.69(m,2H),2.88(m,1H),2.50(s,3H).
[0069] Step 3: Preparation of compound 7
[0070] (3,5-difluoro-4-((6-methylpyridin-3-yl)oxy)phenyl)methanol 7c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes to react. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour to react. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 7 (17 mg, 17.5%).
[0071] 1 H NMR (400 MHz, CDCl 3 )δ 8.27(m,1H),7.10(m,4H),5.62(s,1H),5.39(s,2H),4.07(m,7.3Hz,1H),3.80(m,1H),3.46(m,1H),3.29-3. 21(m,1H),3.15(m,1H),3.04(m,1H),2.50(s,3H),2.43(m,1H),1.97-1.86(m,2H),1.51(m,2H).MS(ESI):m / z 441.0[M+H] + .
[0072] Example 8 Preparation of Compound 8 [ka] [ka] Step 1: Preparation of compound 8b
[0073] At room temperature, 2-methylpyrimidin-5-ol 8a (0.25 g, 2.3 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.44 g, 2.8 mmol) and potassium carbonate (0.41 g, 2.9 mmol) were dissolved in 30 mL N,N-dimethylformamide and reacted at 90 ° C. for 2 hours with stirring. After cooling, 100 mL of ice water was poured into the mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 8b (0.24 g, yield: 41.7%).
[0074] 1 H NMR (400 MHz, CDCl 3 ) δ 9.93 (s, 1H), 8.39 (s, 2H), 7.64-7.54 (m, 2H), 2.72 (s, 3H). Step 2: Preparation of compound 8c
[0075] 3,5-Difluoro-4-((2-methylpyrimidin-5-yl)oxy)benzaldehyde 8b (0.24 g, 0.96 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (30 mg, 0.79 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 8c (0.17 g, yield: 70.2%).
[0076] 1 H NMR (400 MHz, CDCl 3 )δ 8.33(s,2H),7.04(m,2H),4.71(m,2H),2.70(s,3H).
[0077] Step 3: Preparation of compound 8
[0078] (3,5-difluoro-4-((2-methylpyrimidin-5-yl)oxy)phenyl)methanol 8c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 8 (10 mg, 10.3%).
[0079] 1 H NMR (400 MHz, CDCl 3 )δ 8.35(s,2H),7.11(m,2H),5.62(s,1H),5.40(s,2H),4.06(s,1H),3.80(m,1H),3.47(m,1H),3.25( s,1H),3.15(m,1H),3.04(m,1H),2.71(s,3H),2.44(m,1H),1.91(m,2H),1.52(m,2H).MS(ESI):m / z 442.0[M+H] + .
[0080] Example 9 Preparation of Compound 9 [ka] [ka] Step 1: Preparation of compound 9b
[0081] At room temperature, 2-(trifluoromethyl)pyrimidin-5-ol 9a (0.25 g, 1.52 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.29 g, 1.81 mmol) and potassium carbonate (0.27 g, 1.98 mmol) were dissolved in 20 mL N,N-dimethylformamide and reacted at 90 ° C. for 2 hours with stirring. After cooling, 100 mL of ice water was poured in and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 9b (0.24 g, yield: 51.9%).
[0082] 1 H NMR (400 MHz, CDCl 3 )δ 9.97(s,1H),8.59(s,2H),7.69-7.54(m,2H).
[0083] Step 2: Preparation of compound 9c
[0084] 3,5-Difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)benzaldehyde 9b (0.24 g, 0.79 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (30 mg, 0.79 mmol) was added, and the reaction was stirred at room temperature for 0.5 h, concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate (100 mL × 2). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 9c (0.12 g, yield: 49.6%).
[0085] 1 H NMR (400 MHz, CDCl 3 )δ 8.54(s,2H),7.12(m,2H),4.74(m,2H),2.23(m,1H).
[0086] Step 3: Preparation of compound 9
[0087] (3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)phenyl)methanol 9c (73 mg, 0.24 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 9 (8 mg, 7.3%).
[0088] 1 H NMR (400 MHz, CDCl 3 )δ 8.58(s,2H),7.19(m,2H),5.66(s,1H),5.45(s,2H),4.10(m,7.4Hz,1H),3.82(m,1H),3.49(m,1H),3. 34-3.23(m,1H),3.18(m,1H),3.07(m,1H),2.47(m,1H),1.97(m,2H),1.60-1.50(m,2H).MS(ESI):m / z 496.1[M+H] + .
[0089] Example 10 Preparation of Compound 10 [ka] [ka] Step 1: Preparation of compound 10b
[0090] At room temperature, 3-(trifluoromethyl)phenol 10a (1g, 6.2mmol), 3,4,5-trifluorobenzaldehyde 4a (1.09g, 6.8mmol) and potassium carbonate (1.1g, 8.02mmol) were dissolved in 30mL N,N-dimethylformamide, and stirred at 90℃ for 2 hours to react. After cooling, 100mL of ice water was poured in, and the mixture was extracted with ethyl acetate (50mL×3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate=10 / 1) to obtain a yellow solid product 10b (1.7g, yield: 90.7%).
[0091] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(s,1H),7.63-7.55(m,2H),7.46(m,1H),7.39(m,1H),7.21(s,1H),7.13(m,1H).
[0092] Step 2: Preparation of compound 10c
[0093] 3,5-Difluoro-4-(3-(trifluoromethyl)phenoxy)benzaldehyde 10b (1.7 g, 5.6 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (213 mg, 5.6 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain a colorless oily product 10c (1.27 g, yield: 74.5%).
[0094] Step 3: Preparation of compound 10
[0095] (3,5-difluoro-4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 10c (73 mg, 0.24 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 10 (6 mg, 5.5%).
[0096] 1 H NMR (400 MHz, CDCl 3 )δ 7.42(m,1H),7.33(m,1H),7.20(s,1H),7.10(m,3H),5.63(s,1H),5.41(s,2H),4.11-4.02(m,1H),3.80(m,1H),3. 47(m,1H),3.26(m,1H),3.15(m,1H),3.04(m,1H),2.43(m,1H),2.00-1.85(m,2H),1.55-1.48(m,2H).MS(ESI):m / z 494.0[M+H] + .
[0097] Example 11 Preparation of Compound 11 [ka] [ka] Step 1: Preparation of compound 11b
[0098] At room temperature, 4-chloro-3-methylphenol 11a (1g, 7.0mmol), 3,4,5-trifluorobenzaldehyde 5a (1.2g, 7.5mmol) and potassium carbonate (1.3g, 9.1mmol) were dissolved in 30mL N,N-dimethylformamide, and stirred at 90℃ for 2 hours to react. After cooling, 100mL of ice water was poured in and extracted with ethyl acetate (50mL×3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate=10 / 1) to obtain a yellow solid product 11b (1.2g, yield: 60.6%).
[0099] 1 H NMR (400 MHz, CDCl 3 )δ 9.92(s,1H),7.61-7.51(m,2H),7.30-7.23(m,1H),6.85(m,1H),6.73(m,1H),2.34(s,3H).
[0100] Step 2: Preparation of compound 11c
[0101] 4-(4-chloro-3-methylphenoxy)-3,5-difluorobenzaldehyde 11b (1.2 g, 4.2 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (161 mg, 4.2 mmol) was added, and the reaction was stirred at room temperature for 0.5 hours, concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the drying agent was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain a colorless oily product 11c (0.89 g, yield: 74.4%).
[0102] Step 3: Preparation of compound 11
[0103] 4-(4-chloro-3-methylphenoxy)-3,5-difluorobenzyl alcohol 11c (77 mg, 0.27 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.42 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes to react. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour to react. A small amount of water was then added to quench the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 11 (9 mg, 8.6%).
[0104] 1 H NMR (400 MHz, CDCl 3 )δ 7.27(m,1H),7.12(m,2H),6.86(m,1H),6.74(m,1H),5.66(s,1H),5.43(s,2H),4.11(m,1H),3.84(m,1H),3.50( m,1H),3.34-3.25(m,1H),3.19(m,1H),3.08(m,1H),2.47(m,1H),2.36(s,3H),1.98(m,2H),1.61-1.51(m,2H).
[0105] Example 12 Preparation of Compound 12 [ka] [ka] Step 1: Preparation of compound 12b
[0106] At room temperature, 3-(trifluoromethoxy)phenol 12a (0.50 g, 2.8 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.5 g, 3.1 mmol) and potassium carbonate (0.5 g, 3.64 mmol) were dissolved in 30 mL N,N-dimethylformamide, and stirred at 90 ° C for 2 hours to react. After cooling, 100 mL of ice water was poured in and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 12b (0.73 g, yield: 91.8%).
[0107] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(s,1H),7.64-7.54(m,2H),7.34(m,1H),7.00(m,1H),6.87(m,2H).
[0108] Step 2: Preparation of compound 12c
[0109] 4-(3-(trifluoromethoxy)phenoxy)-3,5-difluorobenzaldehyde 12b (0.73 g, 2.3 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (86 mg, 2.28 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 12c (0.57 g, yield: 77.4%).
[0110] 1 H NMR (400 MHz, CDCl 3)δ 7.30(m,1H),7.06(m,2H),6.94(m,1H),6.85(m,1H),6.81(s,1H),4.72(m,2H),1.94(m,1H).
[0111] Step 3: Preparation of compound 12
[0112] 4-(3-(trifluoromethoxy)phenoxy)-3,5-difluorophenyl)methanol 12c (70 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes to react. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour to react. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 12 (6 mg, 5.4%).
[0113] 1 H NMR (400 MHz, CDCl 3 )δ 7.29(m,1H),7.08(m,2H),6.93(m,1H),6.88-6.77(m,2H),5.62(s,1H),5.39(s,2H),4.06(m,1H),3.81(m,1H), 3.46(m,1H),3.31-3.20(m,1H),3.13(m,1H),3.04(m,1H),2.43(m,1H),1.89(m,2H),1.51(m,2H).MS(ESI):m / z 510.0[M+H] + .
[0114] Example 13 Preparation of Compound 13 [ka] [ka] Step 1: Preparation of compound 13b
[0115] At room temperature, 4-(trifluoromethyl)phenol 13a (0.84 g, 5.2 mmol), 3,4,5-trifluorobenzaldehyde 5a (1 g, 6.2 mmol) and potassium carbonate (0.93 g, 6.76 mmol) were dissolved in 30 mL N,N-dimethylformamide, stirred at 90 ° C for 1 h, cooled to room temperature, poured into 100 mL ice water, extracted with ethyl acetate (50 mL × 3), combined organic phase, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered to remove the desiccant, concentrated the filtrate under reduced pressure, and purified by silica gel column chromatography with eluent system (petroleum ether / ethyl acetate = 5 / 1) to obtain yellow solid product 13b (1.33 g, yield: 84.6%).
[0116] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(m,1H),7.59(m,4H),7.04(m,2H).
[0117] Step 2: Preparation of compound 13c
[0118] 3,5-Difluoro-4-(4-(trifluoromethyl)phenoxy)benzaldehyde 13b (1.33 g, 4.4 mmol) was dissolved in 50 mL of methyl ethanol at room temperature and added to NaBH 4 (166 mg, 4.4 mmol) was added, and the reaction was stirred at room temperature for 0.5 hours, concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the drying agent was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 2 / 1) to obtain colorless oily product 13c (0.85 g, yield: 63.5%).
[0119] 1 H NMR (400 MHz, CDCl 3 )δ 7.57(m,2H),7.09-7.00(m,4H),4.72(m,2H),2.03(m,1H).
[0120] Step 3: Preparation of compound 13
[0121] 3,5-Difluoro-4-(4-(trifluoromethyl)phenoxy)phenyl)methanol 13c (67mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18mg, 0.44mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 1f (50mg, 0.22mmol) was added and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 13 (11mg, 10.1%).
[0122] 1 H NMR (400 MHz, CDCl 3 )δ 7.57(m,2H),7.10(m,2H),7.01(m,2H),5.63(s,1H),5.41(s,2H),4.11-4.04(m,1H),3.80(m,1H),3.47(m,1H) ,3.30-3.21(m,1H),3.16(m,1H),3.04(m,1H),2.44(m,1H),1.99-1.85(m,2H),1.57-1.48(m,2H).MS(ESI):m / z 494.0[M+H] + .
[0123] Example 14 Preparation of Compound 14 [ka] [ka] Step 1: Preparation of compound 14b
[0124] At room temperature, 4-chloro-3-(trifluoromethyl)phenol 14a (0.5 g, 2.5 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.45 g, 2.8 mmol) and potassium carbonate (0.46 g, 3.3 mmol) were dissolved in 30 mL N,N-dimethylformamide, and stirred at 90 ° C for 2 hours. After cooling, 100 mL of ice water was poured in and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain yellow solid product 14b (0.6 g, yield: 71.3%).
[0125] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(s,1H),7.64-7.55(m,2H),7.45(m,1H),7.31(m,1H),7.05(m,1H).
[0126] Step 2: Preparation of compound 14c
[0127] 4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzaldehyde 14b (0.6 g, 1.78 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (67 mg, 1.78 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain white solid product 14c (0.28 g, yield: 46.4%).
[0128] 1 H NMR (400 MHz, CDCl 3)δ 7.41(m,1H),7.28(m,1H),7.08-7.00(m,3H),4.73(m,2H),1.94(m,1H).
[0129] Step 3: Preparation of compound 14
[0130] (4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorophenyl)methanol 14c (74 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 14 (22 mg, 18.9%).
[0131] 1 H NMR (400 MHz, CDCl 3 )δ 7.41(m,1H),7.30(m,1H),7.11(m,2H),7.01(m,1H),5.63(s,1H),5.41(s,2H),4.07(m,1H),3.80(m,1H) ,3.47(m,1H),3.30-3.21(m,1H),3.15(m,1H),3.04(m,1H),2.44(m,1H),1.95(m,2H),1.57-1.47(m,2H).
[0132] Example 15 Preparation of Compound 15 [ka] [ka] Step 1: Preparation of compound 15b
[0133] At room temperature, 3-chloro-4-(trifluoromethoxy)phenol 15a (0.50 g, 2.4 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.41 g, 2.6 mmol) and potassium carbonate (0.42 g, 3.04 mmol) were dissolved in 20 mL N,N-dimethylformamide, and the mixture was stirred at 90 ° C for 2 hours. After cooling, 100 mL of ice water was poured in and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain a yellow solid product 15b (0.62 g, yield: 73.2%).
[0134] 1 H NMR (400 MHz, CDCl 3 )δ 9.94(s,1H),7.63-7.54(m,2H),7.29(m,1H),7.07(m,1H),6.90(m,1H).
[0135] Step 2: Preparation of compound 15c
[0136] 4-(3-chloro-4-(trifluoromethoxy)phenoxy)-3,5-difluorobenzaldehyde 15b (0.62 g, 1.8 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (62 mg, 1.94 mmol) was added, and the mixture was stirred at room temperature for 0.5 h to react, concentrated under reduced pressure, added with water, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain colorless oily product 15c (0.53 g, yield: 83.0%).
[0137] 1 H NMR (400 MHz, CDCl 3)δ 7.25(m,1H),7.06(m,2H),7.01(m,1H),6.87(m,1H),4.72(s,2H),2.04(m,1H).
[0138] Step 3: Preparation of compound 15
[0139] (4-(3-chloro-4-(trifluoromethoxy)phenoxy)-3,5-difluorophenyl)methanol 15c (79 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.44 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 1f (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 15 (7 mg, 5.8%).
[0140] 1 H NMR (400 MHz, CDCl 3 )δ 7.24(m,1H),7.10(m,2H),7.03(m,1H),6.87(m,1H),5.63(s,1H),5.41(s,2H),4.10-4.03(m,1H),3.80(m,1) H),3.47(m,1H),3.30-3.21(m,1H),3.16(m,1H),3.04(m,1H),2.44(m,1H),1.95(m,2H),1.56-1.49(m,2H).
[0141] Example 16 Preparation of Compound 16 [ka] [ka] Step 1: Preparation of compound 16b
[0142] At room temperature, 3-chloro-4-(trifluoromethyl)phenol 16a (0.25 g, 1.23 mmol), 3,4,5-trifluorobenzaldehyde 5a (0.22 g, 1.4 mmol) and potassium carbonate (0.23 g, 1.65 mmol) were dissolved in 20 mL N,N-dimethylformamide, and stirred at 90 ° C for 2 hours. After cooling, 100 mL of ice water was poured in and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 10 / 1) to obtain yellow solid product 16b (0.32 g, yield: 77.3%).
[0143] 1 H NMR (400 MHz, CDCl 3 )δ 9.95(s,1H),7.69-7.56(m,3H),7.10(m,1H),6.92(m,1H).
[0144] Step 2: Preparation of compound 16c
[0145] 4-(3-chloro-4-(trifluoromethyl)phenoxy)-3,5-difluorobenzaldehyde 16b (0.32 g, 0.95 mmol) was dissolved in 50 mL of methanol at room temperature and added to NaBH 4 (36 mg, 0.94 mmol) was added, and the reaction was stirred at room temperature for 0.5 hours, concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the drying agent was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (petroleum ether / ethyl acetate = 4 / 1) to obtain white solid product 16c (0.15 g, yield: 46.6%).
[0146] 1 H NMR (400 MHz, CDCl 3)δ 7.62(m,1H),7.13-7.00(m,3H),6.90(m,1H),4.74(m,2H),1.88(m,1H).
[0147] Step 3: Preparation of compound 16
[0148] (4-(3-chloro-4-(trifluoromethyl)phenoxy)-3,5-difluorophenyl)methanol (74.5mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18mg, 0.44mmol) was added at 0°C, and the mixture was stirred at room temperature for 5 minutes, and then compound 1f (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 16 (13mg, 11.2%).
[0149] 1 H NMR (400 MHz, CDCl 3 )δ 7.62(m,1H),7.12(m,2H),7.07(m,1H),6.90(m,1H),5.63(s,1H),5.42(s,2H),4.12-4.03(m,1H),3.81(m,1) H),3.45(m,1H),3.32-3.21(m,1H),3.16(m,1H),3.05(m,1H),2.44(m,1H),1.91(m,2H),1.56-1.49(m,2H).
[0150] Example 17 Preparation of Compound 17 [ka] Step 1: Preparation of compound 17b [ka] At room temperature, 6-chlorouracil (8.2 g, 55.9 mmol), (S)-3-(hydroxymethyl)piperidine-1-carboxylate t-butyl 17a (12 g, 55.7 mmol) and triphenylphosphine (20 g, 76.2 mmol) were dissolved in a mixed solvent of 250 mL of anhydrous tetrahydrofuran and 50 mL of anhydrous N,N-dimethylformamide, and diisopropyl azodicarboxylate (20 ml, 111.6 mmol) was added dropwise at 0°C under nitrogen protection. The mixture was stirred at 0°C for 2 hours and reacted, then warmed to room temperature and reacted overnight. The reaction solution was filtered and extracted with ethyl acetate (50mL x 3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified using silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain colorless oily product 17b (7.8g, yield: 40.6%).
[0151] Steps 2 and 3: Preparation of compound 17d [ka] At room temperature, compound (S)-3-(((6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)piperidine-1-carboxylate t-butyl 17b (7.8 g, 22.7 mmol) was dissolved in 80 mL of dichloromethane, and 10 mL of trifluoroacetic acid was added at 0° C., and the mixture was stirred at room temperature for 2 hours to react. The reaction solution was concentrated under reduced pressure, and the next reaction was carried out directly. The crude product of the previous step was dissolved in 80 mL of acetonitrile, and diisopropylethylamine (8.8 g, 68.1 mmol) was added at room temperature, and the mixture was stirred for 4 hours to react. The mixture was concentrated under reduced pressure, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 17d (1.5 g, 31.9%).
[0152] 1 H NMR (400 MHz, CDCl 3)δ 9.51(s,1H),5.35(s,1H),4.03(m,1H),3.78-3.64(m,1H),3.43(m,1H),3.24( m,1H),3.18-2.96(m,2H),2.37(m,1H),2.00-1.83(m,2H),1.72-1.49(m,2H).
[0153] Step 4: Preparation of compound 17e [ka] Compound 17d (0.51 g, 2.46 mmol) and dimethylaniline (0.3 g, 2.47 mmol) were dissolved in toluene at room temperature, and phosphorus oxychloride (0.76 g, 4.96 mmol) was added dropwise. The mixture was heated under reflux for 4 hours, and then the reaction was quenched with ice water, concentrated under reduced pressure, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain white solid product 17e (0.24 g, 43.2%).
[0154] 1 H NMR (400 MHz, CDCl 3 )δ 6.05(s,1H),4.04(m,1H),3.74(m,1H),3.51(m,1H),3.28(m,1H),3.20- 3.14(m,1H),3.01(m,1H),2.51(m,1H),1.92(m,2H),1.59-1.41(m,2H).
[0155] Step 5: Preparation of compound 17 [ka] (3,5-difluoro-4-((2-(trifluoromethylpyridin-4-yl)oxy)phenyl)methanol 5d (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 18 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 17e (50 mg, 0.22 mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 17 (28 mg, 25.7%).
[0156] 1 H NMR (400 MHz, CDCl 3 )δ 8.59(m,1H),7.25(s,1H),7.15(m,2H),6.98(m,1H),5.63(s,1H),5.42(s,2H),4.07(m,1H),3.80(m,1H), 3.46(m,1H),3.27(m,1H),3.16(m,1H),3.03(m,1H),2.44(m,1H),1.90(m,2H),1.52(m,2H).MS(ESI):m / z 495.1[M+H] + .
[0157] Example 18 Preparation of Compound 18 [ka] (3,5-difluoro-4-((6-methylpyridin-3-yl)oxy)phenyl)methanol 7c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 17e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 18 (22 mg, 22.7%).
[0158] 1 H NMR (400 MHz, CDCl 3 )δ 8.27(m,1H),7.10(m,4H),5.62(s,1H),5.39(s,2H),4.07(m,1H),3.80(m,1H),3.46(m,1H),3.29-3.21( m,1H),3.15(m,1H),3.04(m,1H),2.51(s,3H),2.44(m,1H),1.99-1.84(m,2H),1.51(m,2H).MS(ESI):m / z 441.2[M+H] + .
[0159] Example 19 Preparation of Compound 19 [ka] (3,5-difluoro-4-((2-methyl)pyridin-4-yl)oxy)phenyl)methanol 6c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 17e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 19 (58 mg, 59.8%).
[0160] 1 H NMR (400 MHz, CDCl 3 )δ 8.35(m,1H),7.10(m,2H),6.67(m,2H),5.62(s,1H),5.41(s,2H),4.07(m,1H),3.79(m,1H),3.46(m,1H),3.30- 3.18(m,1H),3.15(m,1H),3.04(m,1H),2.50(s,3H),2.43(m,1H),1.91(m,2H),1.55-1.46(m,2H).MS(ESI):m / z 441.2[M+H] + .
[0161] Example 20 Preparation of Compound 20 [ka] (3,5-difluoro-4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 10c (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 17e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 20 (46 mg, 42.4%).
[0162] 1 H NMR (400 MHz, CDCl 3 )δ 7.41(m,1H),7.32(m,1H),7.19(s,1H),7.09(m,3H),5.62(s,1H),5.40(s,2H),4.06(m,1H),3.79(m,1H),3.46(m, 1H),3.30-3.19(m,1H),3.14(m,1H),3.03(m,1H),2.43(m,1H),1.98-1.84(m,2H),1.57-1.46(m,2H).MS(ESI):m / z 494.1[M+H] + .
[0163] Example 21 Preparation of Compound 21 [ka] 3,5-Difluorobenzyl alcohol (32mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 17e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 21 (17mg, 23.2%).
[0164] 1 H NMR (400 MHz, CDCl 3 )δ 6.96-6.87(m,2H),6.74(m,1H),5.60(s,1H),5.37(s,2H),4.06(m,1H),3.79(m,1H),3.45(m,1H),3. 23(m,1H),3.14(m,1H),3.03(m,1H),2.42(m,1H),1.99-1.83(m,2H),1.57-1.46(m,2H).MS(ESI):m / z 334.1[M+H] + .
[0165] Example 22 Preparation of Compound 22 [ka] 2,4,5-trifluorobenzyl alcohol (36mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 17e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain the white solid target product 22 (36mg, 46.6%).
[0166] 1 H NMR (400 MHz, CDCl 3)δ 7.32(m,1H),6.94(m,1H),5.57(s,1H),5.40(s,2H),4.06(m,1H),3.79(m,1H),3.44(m,1H),3.29-3. 17(m,1H),3.14(m,1H),3.03(m,1H),2.42(m,1H),1.99-1.83(m,2H),1.55-1.45(m,2H).MS(ESI):m / z 352.1[M+H] + .
[0167] Example 23 Preparation of Compound 23 [ka] Step 1: Preparation of compound 23b [ka] At room temperature, 6-chlorouracil (6.1 g, 41.6 mmol), (R)-3-(hydroxymethyl)piperidine-1-carboxylate t-butyl 23a (9 g, 41.8 mmol), and triphenylphosphine (16.3 g, 62.1 mmol) were dissolved in a mixed solvent of 250 mL of anhydrous tetrahydrofuran and 50 mL of anhydrous N,N-dimethylformamide, and diisopropyl azodicarboxylate (16 ml, 83 mmol) was added dropwise at 0°C under nitrogen protection. After stirring at 0°C for 2 hours, the mixture was allowed to react and then warmed to room temperature overnight. The reaction solution was filtered and extracted with ethyl acetate (50mL x 3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified using silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain colorless oily product 23b (8.3g, yield: 58.0%).
[0168] Steps 2 and 3: Preparation of compound 23d [ka] At room temperature, compound (R)-3-(((6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)piperidine-1-carboxylate t-butyl 23b (8.3 g, 24.1 mmol) was dissolved in 80 mL of dichloromethane, and 10 mL of trifluoroacetic acid was added at 0° C., and the mixture was stirred at room temperature for 2 hours to react. The reaction solution was concentrated under reduced pressure, and the next reaction was carried out directly. The crude product of the previous step was dissolved in 80 mL of acetonitrile, and potassium carbonate (7.0 g, 50.9 mmol) was added at room temperature, and the mixture was heated under reflux overnight to react. The mixture was filtered, and the filter cake was rinsed with acetonitrile and methanol, respectively. The filtrate was concentrated under reduced pressure, and purified using silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 23d (1.5 g, 29.9%).
[0169] 1 H NMR (400 MHz, CDCl 3 )δ 8.85(s,1H),5.33(s,1H),4.01(m,1H),3.70(m,1H),3.42(m,1H),3.23(m,1H) ,3.11(m,1H),3.03(m,1H),2.35(m,1H),1.99-1.82(m,2H),1.67-1.47(m,2H).
[0170] Step 4: Preparation of compound 23e [ka] Compound 23d (0.5 g, 2.4 mmol) and dimethylaniline (0.29 g, 2.4 mmol) were dissolved in toluene at room temperature, and phosphorus oxychloride (0.74 g, 4.8 mmol) was added dropwise. The mixture was heated under reflux for 4 hours, and then the reaction was quenched with ice water, concentrated under reduced pressure, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain white solid product 23e (0.31 g, 57.2%).
[0171] 1 H NMR (400 MHz, CDCl 3 )δ 6.05(s,1H),4.05(m,1H),3.76(m,1H),3.51(m,1H),3.28(m,1H),3.22-3. 13(m,1H),3.02(m,1H),2.52(m,1H),2.01-1.82(m,2H),1.61-1.39(m,2H).
[0172] Step 5: Preparation of compound 23 [ka] (3,5-difluoro-4-((2-(trifluoromethylpyridin-4-yl)oxy)phenyl)methanol 5d (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 23e (50 mg, 0.22 mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 23 (25 mg, 23.0%).
[0173] 1 H NMR (400 MHz, CDCl 3 )δ 8.59(m,1H),7.25(s,1H),7.14(m,2H),6.98(m,1H),5.63(s,1H),5.42(s,2H),4.07(m,1H),3.79(m,1H),3.46( m,1H),3.26(m,1H),3.15(m,1H),3.04(m,1H),2.44(m,1H),2.00-1.84(m,2H),1.56-1.46(m,2H).MS(ESI):m / z 495.1[M+H] + .
[0174] Example 24 Preparation of Compound 24 [ka] (3,5-difluoro-4-((6-methylpyridin-3-yl)oxy)phenyl)methanol 7c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 23e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 24 (52 mg, 53.7%).
[0175] 1 H NMR (400 MHz, CDCl 3 )δ 8.27(m,1H),7.09(m,4H),5.61(s,1H),5.38(s,2H),4.06(m,1H),3.80(m,1H),3.46(m,1H),3.28-3.20( m,1H),3.15(m,1H),3.04(m,1H),2.51(s,3H),2.43(m,1H),1.92(m,2H),1.57-1.45(m,2H).MS(ESI):m / z 441.2[M+H] + .
[0176] Example 25 Preparation of Compound 25 [ka] (3,5-difluoro-4-((2-methyl)pyridin-4-yl)oxy)phenyl)methanol 6c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 23e (50 mg, 0.22 mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid target product 25 (38 mg, 39.2%).
[0177] 1 H NMR (400 MHz, CDCl 3 )δ 8.36(m,1H),7.11(m,2H),6.67(m,2H),5.63(s,1H),5.41(s,2H),4.07(m,1H),3.80(m,1H),3.47(m,1H),3.32-3. 21(m,1H),3.15(m,1H),3.04(m,1H),2.51(s,3H),2.44(m,1H),2.00-1.83(m,2H),1.59-1.46(m,2H).MS(ESI):m / z 441.2[M+H] + .
[0178] Example 26 Preparation of Compound 26 [ka] (3,5-difluoro-4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 10c (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 23e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 26 (58 mg, 53.4%).
[0179] 1 H NMR (400 MHz, CDCl 3 )δ 7.42(m,1H),7.33(m,1H),7.20(s,1H),7.11(m,3H),5.63(s,1H),5.41(s,2H),4.07(m,1H),3.80(m,1H),3.47(m, 1H),3.30-3.20(m,1H),3.15(m,1H),3.04(m,1H),2.43(m,1H),1.98-1.84(m,2H),1.56-1.48(m,2H).MS(ESI):m / z 494.1[M+H] + .
[0180] Example 27 Preparation of Compound 27 [ka] 3,5-Difluorobenzyl alcohol (32mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 23e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 27 (19mg, 25.9%).
[0181] 1 H NMR (400 MHz, CDCl 3 )δ 6.96-6.87(m,2H),6.73(m,1H),5.58(s,1H),5.37(s,2H),4.05(m,1H),3.79(m,1H),3.45(m,1H),3.29- 3.19(m,1H),3.14(m,1H),3.03(m,1H),2.41(m,1H),1.98-1.82(m,2H),1.55-1.46(m,2H).MS(ESI):m / z 334.1[M+H] + .
[0182] Example 28 Preparation of Compound 28 [ka] 2,4,5-trifluorobenzyl alcohol (36mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 23e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 28 (18mg, 23.3%).
[0183] 1 H NMR (400 MHz, CDCl 3 )δ 7.32(m,1H),6.95(m,1H),5.58(s,1H),5.40(s,2H),4.06(m,1H),3.79(m,1H),3.44(m,1H),3.29- 3.19(m,1H),3.14(m,1H),3.03(m,1H),2.43(m,1H),1.93(m,2H),1.55-1.46(m,2H).MS(ESI):m / z 352.1[M+H] + .
[0184] Example 29 Preparation of Compound 29 [ka] Step 1: Preparation of compound 29b [ka] At room temperature, 6-chlorouracil (10 g, 69 mmol), (S)-2-(hydroxymethyl)morpholine-4-carboxylate t-butyl 29a (15 g, 69 mmol) and triphenylphosphine (27 g, 102.9 mmol) were dissolved in a mixed solvent of 250 mL of anhydrous tetrahydrofuran and 50 mL of anhydrous N,N-dimethylformamide. Under nitrogen protection, diisopropyl azodicarboxylate (27 ml, 138 mmol) was added dropwise at 0°C and reacted with stirring at 0°C for 2 hours. The reaction solution was then warmed to room temperature and reacted overnight. The reaction solution was filtered, extracted with ethyl acetate (50 mL x 3), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and diluted with 100 mL of ethyl acetate. After adding PE / EA=3 / 1, a large amount of white solid precipitated. The reaction solution was filtered, concentrated under reduced pressure, and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain colorless oily product 29b (11.5 g, yield: 48.2%).
[0185] Steps 2 and 3: Preparation of compound 29d [ka] At room temperature, compound (S)-2-(((6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)morpholine-4-carboxylate t-butyl 29b (11.5 g, 33.2 mmol) was dissolved in 80 mL of dichloromethane, and 10 mL of trifluoroacetic acid was added at 0° C., and the mixture was stirred at room temperature for 2 hours to react. The reaction solution was concentrated under reduced pressure and directly subjected to the next reaction. The crude product of the previous step was dissolved in 80 mL of acetonitrile, and potassium carbonate (9.2 g, 67 mmol) was added at room temperature, and the mixture was heated under reflux overnight to react. The mixture was filtered, and the filter cake was rinsed with acetonitrile and methanol, respectively. The filtrate was concentrated under reduced pressure and purified using silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 29d (1.9 g, 27.4%).
[0186] 1 H NMR (400 MHz, CDCl 3)δ 9.39(s,1H),5.41(s,1H),4.36-4.28(m,1H),4.05(m,1H),3.95(m,1H),3. 78(m,1H),3.69-3.55(m,2H),3.44-3.37(m,1H),3.24(m,1H),2.96(m,1H).
[0187] Step 4: Preparation of compound 29e [ka] Compound 29d (0.5 g, 2.4 mmol) and dimethylaniline (0.29 g, 2.4 mmol) were dissolved in toluene at room temperature, and phosphorus oxychloride (0.73 g, 4.8 mmol) was added dropwise. The mixture was heated under reflux for 4 hours, and then the reaction was quenched with ice water, concentrated under reduced pressure, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain white solid product 29e (0.3 g, 54.9%).
[0188] 1 H NMR (400 MHz, CDCl 3 )δ 6.12(s,1H),4.49(m,1H),4.08(m,1H),3.99(m,1H),3.72-3.61(m,3H),3.48(m,1H),3.37(m,1H),2.96(m,1H).
[0189] Step 5: Preparation of compound 29 [ka] (3,5-difluoro-4-((2-(trifluoromethylpyridin-4-yl)oxy)phenyl)methanol 5d (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50 mg, 0.22 mmol) was added and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 29 (31 mg, 28.4%).
[0190] 1 H NMR (400 MHz, CDCl 3 )δ 8.59(m,1H),7.25(s,1H),7.14(m,2H),6.98(m,1H),5.69(s,1H),5.43(s,2H),4.40(m,1H),4. 12(m,1H),4.03(m,1H),3.70-3.57(m,3H),3.44(m,1H),3.27(m,1H),2.95(m,1H).MS(ESI):m / z 497.1[M+H] + .
[0191] Example 30 Preparation of Compound 30 [ka] (3,5-difluoro-4-((6-methylpyridin-3-yl)oxy)phenyl)methanol (56mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0°C, and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 30 (49mg, 50.3%).
[0192] 1H NMR (400 MHz, CDCl 3 )δ 8.26(m,1H),7.16-7.05(m,4H),5.69(s,1H),5.40(s,2H),4.40(m,1H),4.13(m,1H),4.04( m,1H),3.70-3.58(m,3H),3.45(m,1H),3.27(m,1H),2.96(m,1H),2.52(s,3H).MS(ESI):m / z 443.1[M+H] + .
[0193] Example 31 Preparation of Compound 31 [ka] (3,5-difluoro-4-((2-methyl)pyridin-4-yl)oxy)phenyl)methanol 6c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50 mg, 0.22 mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid target product 31 (38 mg, 39.0%).
[0194] 1 H NMR (400 MHz, CDCl 3 )δ 8.35(m,1H),7.11(m,2H),6.72-6.63(m,2H),5.70(s,1H),5.42(s,2H),4.39(m,1H),4.17-4.08(m,1H), 4.03(m,1H),3.71-3.57(m,3H),3.50-3.40(m,1H),3.27(m,1H),2.95(m,1H),2.50(s,3H).MS(ESI):m / z 443.1[M+H] + .
[0195] Example 32 Preparation of Compound 32 [ka] (3,5-difluoro-4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 10c (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50 mg, 0.22 mmol) was added and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 32 (31 mg, 28.4%).
[0196] 1 H NMR (400 MHz, CDCl 3 )δ 7.42(m,1H),7.34(m,1H),7.19(s,1H),7.10(m,3H),5.70(s,1H),5.42(s,2H),4.40(m,1H) ,4.17-4.00(m,2H),3.71-3.57(m,3H),3.45(m,1H),3.28(m,1H),2.96(m,1H).MS(ESI):m / z 496.1[M+H] + .
[0197] Example 33 Preparation of Compound 33 [ka] 3,5-Difluorobenzyl alcohol (32mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 33 (21mg, 28.5%).
[0198] 1H NMR (400 MHz, CDCl 3 )δ 6.98-6.91(m,2H),6.77(m,1H),5.70(s,1H),5.40(s,2H),4.41(m,1H),4.14(m,1H), 4.04(m,1H),3.72-3.58(m,3H),3.46(m,1H),3.28(m,1H),2.97(m,1H).MS(ESI):m / z 336.1[M+H] + .
[0199] Example 34 Preparation of Compound 34 [ka] 2,4,5-trifluorobenzyl alcohol (36mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 29e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 34 (29mg, 37.3%).
[0200] 1 H NMR (400 MHz, CDCl 3 )δ 7.36-7.27(m,1H),6.95(m,1H),5.64(s,1H),5.40(s,2H),4.42-4.35(m,1H),4.12(m,1 H),4.02(m,1H),3.73-3.55(m,3H),3.43(m,1H),3.24(m,1H),2.95(m,1H).MS(ESI):m / z 354.1[M+H] + .
[0201] Example 35 Preparation of Compound 35 [ka] Step 1: Preparation of compound 35b [ka] At room temperature, 6-chlorouracil (10 g, 68.2 mmol), (R)-2-(hydroxymethyl)morpholine-4-carboxylate t-butyl 35a (15 g, 69 mmol) and triphenylphosphine (27 g, 102.9 mmol) were dissolved in a mixed solvent of 250 mL of anhydrous tetrahydrofuran and 50 mL of anhydrous N,N-dimethylformamide. Diisopropyl azodicarboxylate (27 ml, 138 mmol) was added dropwise at 0°C under nitrogen protection, and the mixture was stirred at 0°C for 2 hours to react, then warmed to room temperature and reacted overnight. The reaction solution was filtered, extracted with ethyl acetate (50 mL x 3), the organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and concentrated to 100 mL. Upon addition of PE / EA=3 / 1, a large amount of white solid precipitated, which was filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain colorless oily product 35b (7.2 g, yield: 30.5%).
[0202] Steps 2 and 3: Preparation of compound 35d [ka] At room temperature, compound (R)-2-(((6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)morpholine-4-carboxylate t-butyl 35b (7.2 g, 20.8 mmol) was dissolved in 80 mL of dichloromethane, and 10 mL of trifluoroacetic acid was added at 0° C., and the mixture was stirred at room temperature for 2 hours to react. The reaction solution was concentrated under reduced pressure, and the next reaction was carried out directly. The crude product of the previous step was dissolved in 80 mL of acetonitrile, and diisopropylethylamine (8.1 g, 62.7 mmol) was added at room temperature, and the mixture was stirred at room temperature for 4 hours to react. The reaction solution was concentrated under reduced pressure, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 35d (2.5 g, 57.4%).
[0203] 1 H NMR (400 MHz, CDCl3 )δ 9.32(s,1H),5.42(s,1H),4.35-4.29(m,1H),4.07(m,1H),3.96(m,1H),3. 78(m,1H),3.70-3.55(m,2H),3.45-3.36(m,1H),3.24(m,1H),2.96(m,1H).
[0204] Step 4: Preparation of compound 35e [ka] Compound 35d (0.1 g, 0.48 mmol) and dimethylaniline (0.058 g, 0.48 mmol) were dissolved in toluene at room temperature, and phosphorus oxychloride (0.73 g, 4.8 mmol) was added dropwise. The mixture was heated under reflux for 4 hours, and then the reaction was quenched with ice water. The mixture was concentrated under reduced pressure, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 20 / 1) to obtain white solid product 35e (0.04 g, 36.4%).
[0205] 1 H NMR (400 MHz, CDCl 3 )δ 6.12(s,1H),4.48(m,1H),4.06(m,1H),3.99(m,1H),3.73-3.61(m,3H),3.47(m,1H),3.42-3.32(m,1H),2.96(m,1H).
[0206] Step 5: Preparation of compound 35 [ka] (3,5-difluoro-4-((2-(trifluoromethylpyridin-4-yl)oxy)phenyl)methanol 5d (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes, and then compound 35e (50 mg, 0.22 mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to stop the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 35 (41 mg, 37.5%).
[0207] 1 H NMR (400 MHz, CDCl 3 )δ 8.60(m,1H),7.25(s,1H),7.15(m,2H),6.99(m,1H),5.70(s,1H),5.44(s,2H),4.40(m,1H),4. 13(m,1H),4.04(m,1H),3.70-3.58(m,3H),3.44(m,1H),3.28(m,1H),2.96(m,1H).MS(ESI):m / z 497.1[M+H] + .
[0208] Example 36 Preparation of Compound 36 [ka] (3,5-difluoro-4-((6-methylpyridin-3-yl)oxy)phenyl)methanol 7c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 35e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 36 (42 mg, 43.2%).
[0209] 1 H NMR (400 MHz, CDCl 3 )δ 8.21(m,1H),7.06(m,4H),5.65(s,1H),5.37(s,2H),4.36(m,1H),4.13-4.03(m,1H),3.98( m,1H),3.66-3.53(m,3H),3.40(m,1H),3.23(m,1H),2.93(m,1H),2.47(s,3H).MS(ESI):m / z 443.1[M+H] + .
[0210] Example 37 Preparation of Compound 37 [ka] (3,5-difluoro-4-((2-methyl)pyridin-4-yl)oxy)phenyl)methanol 6c (56 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 35e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain the white solid target product 37 (18 mg, 18.5%).
[0211] 1 H NMR (400 MHz, CDCl 3 )δ 8.36(m,1H),7.09(m,2H),6.70-6.65(m,2H),5.70(s,1H),5.43(s,2H),4.41(m,1H),4.13(m,1H), 4.04(m,1H),3.72-3.58(m,3H),3.46(m,1H),3.28(m,1H),2.96(m,1H),2.51(s,3H).MS(ESI):m / z 443.1[M+H] + .
[0212] Example 38 Preparation of Compound 38 [ka] (3,5-Difluoro-4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 10c (67 mg, 0.22 mmol) was dissolved in 5 mL of dried N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11 mg, 0.26 mmol) was added at 0° C., and the mixture was stirred at room temperature for 5 minutes. Compound 35e (50 mg, 0.22 mmol) was then added, and the mixture was stirred for 1 hour. A small amount of water was then added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain a white solid product 38 (55 mg, 50.5%).
[0213] 1 H NMR (400 MHz, CDCl 3 )δ 7.41(m,1H),7.33(m,1H),7.18(s,1H),7.10(m,3H),5.70(s,1H),5.41(s,2H),4.40(m,1H),4.15- 4.07(m,1H),4.03(m,1H),3.70-3.55(m,3H),3.45(m,1H),3.27(m,1H),2.96(m,1H).MS(ESI):m / z 496.1[M+H] + .
[0214] Example 39 Preparation of Compound 39 [ka] 3,5-Difluorobenzyl alcohol (32mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 35e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 39 (37mg, 50.2%).
[0215] 1H NMR (400 MHz, CDCl 3 )δ 6.96-6.89(m,2H),6.75(m,1H),5.68(s,1H),5.39(s,2H),4.40(m,1H),4.12(m,1H), 4.03(m,1H),3.70-3.55(m,3H),3.44(m,1H),3.26(m,1H),2.95(m,1H).MS(ESI):m / z 336.1[M+H] + .
[0216] Example 40 Preparation of Compound 40 [ka] 2,4,5-trifluorobenzyl alcohol (36mg, 0.22mmol) was dissolved in 5mL dry N,N-dimethylformamide, and sodium hydride (60% content in mineral oil, 11mg, 0.26mmol) was added at 0℃, and the mixture was stirred at room temperature for 5 minutes, and then compound 35e (50mg, 0.22mmol) was added, and the mixture was stirred for 1 hour, and then a small amount of water was added to terminate the reaction, and the mixture was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol=20 / 1) to obtain white solid target product 40 (39mg, 50.2%).
[0217] 1 H NMR (400 MHz, CDCl 3 )δ 7.36-7.28(m,1H),6.95(m,1H),5.65(s,1H),5.41(s,2H),4.42-4.35(m,1H),4.17-4.08(m ,1H),4.03(m,1H),3.71-3.55(m,3H),3.44(m,1H),3.25(m,1H),2.95(m,1H).MS(ESI):m / z 354.1[M+H] + .
[0218] Biological evaluation The biological activity of the compounds can be determined by using any suitable assay and tissue or in vivo model that measures the activity of the compounds as LpPLA2 inhibitors.
[0219] (1) Recombinant human Lp-PLA2 assay (rhLp-PLA2), also known as the PED6 assay
[0220] PED6 is a fluorescently labeled phospholipid, available directly from Invitrogene or Molecular Probes. A p-nitrophenyl group for fluorescence quenching is attached to the 3-position of Sn, and a Bodipy fluorescein (FL) group is attached to the 2-position of sn. When PED6 is broken down by the Lp-PLA2 enzyme, the FL group is released, and the fluorescence is enhanced. However, when an Lp-PLA2 inhibitor inhibits the occurrence of such destruction, the fluorescence enhancement is not observed.
[0221] Measurement method: The compounds to be measured (as shown in Table 1) were mixed with DMSO solution at a volume ratio of 1:3, and diluted into the source plate of a 384-well microplate. Then, 0.01 μL of the compounds were transferred from the source plate to a 384-well Greiner 784076 plate using an ECHO liquid handler, and 5 μL of a buffer solution consisting of 50 mM HEPES, pH 7.4, 150 mM NaCl, and 1 mM CHAPS (containing recombinant human Lp-PLA2 enzyme at a concentration of 4 nM or 110 pM) was added to each well of the plate. The plate was centrifuged at 500 rpm for 10 seconds, and after 30 minutes of pre-incubation, 5 μL of the above buffer was added to the 384-well Greiner 784076 plate, the plate was centrifuged at 500 rpm for 10 seconds, and incubated at room temperature for 20 minutes in the dark. The fluorescence intensity was then read at ex480 / em540 using a ViewLux microplate imager, and curve and QC analysis was performed using Excel's XL regression model to calculate the pIC50. The results are summarized in Table 1.
[0222] [Table 1]
[0223] (2) Human plasma Lp-PLA2 measurement (also called Thio-PAF measurement) For human plasma measurement, a sulfatide analogue of PAF (phosphatidylcholine) is used, which is hydrolyzed to produce a phospholipid containing a free mercapto group, which is subjected to Michael addition with CPM to produce a maleimide that enhances fluorescence, and the fluorescence intensity is measured to allow continuous quantitative analysis of mercaptans. This method allows the inhibition activity of Lp-PLA2 inhibitors against the Lp-PLA2 enzyme in human plasma to be measured.
[0224] Measurement method: The compounds to be measured (as shown in Table 2) were mixed with DMSO solution at a volume ratio (1:3) and diluted into the source plate of a 384-well microplate. Using an ECHO liquid handler, 0.01 μL of the compounds were transferred from the source plate to a 384-well Greiner 784076 small volume plate, and then 8 μL of pre-frozen mixed human plasma was added. The plate was centrifuged at 500 rpm for 10 seconds and after a 30 minute preincubation, 2 μL of substrate solution containing 2.5 mM 2-thioPAF (in ethanol), 32 μM CPM (in DMSO) and 3.2 mM N-ethylmaleimide (NEM) in buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM CHAPS) was added to a 384-well Greiner 784076 low volume plate using a BRAVO liquid handling system. After 2 minutes, the reaction was stopped with 5 μL 5% trifluoroacetic acid and incubated at room temperature for 40 minutes in the dark. Fluorescence intensities were read using an Envision microplate reader with ex380 / em485, and curve and QC analysis was performed using Excel's XL regression model to calculate pIC50s, with the results summarized in Table 2.
[0225] [Table 2]
Claims
1. A compound of formula (I) or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (I) During the ceremony, n 1 , n 2 is 1, n 3 is 0, 1 or 2, R 1 , R 2 are each independently selected from -H, a hydroxyl group, a cyano group, a halogen, an alkyl group, a deuterated alkyl group, a deuterated alkoxy group, a hydroxyalkyl group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, or an alkoxy group; X 1 , X 2 are each independently selected from an alkylene group, —O—, —S—, or —NR′—; R' is selected from -H, an alkyl group, a deuterated alkyl group, or a cycloalkyl group; Ar is an arylene group or a heteroarylene group, a hydrogen atom in the arylene group or the heteroarylene group may be substituted with one or more substituents, each of which is independently selected from a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a deuterated alkoxy group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, an amino group substituted with a monoalkyl group or a dialkyl group, a nitro group, a carboxyl group, an aldehyde group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; Y is -H, a halogen, an alkyl group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, an alkoxy group, a deuterated alkyl group, a deuterated alkoxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, -OAr', -SAr', -NR''-Ar', -NR''R'', or -R'''-Ar'; Ar' is selected from an aryl group or a heteroaryl group, and a hydrogen atom in the aryl group or the heteroaryl group may be substituted with one or more substituents, each of which is independently selected from a halogen, an alkyl group, a haloalkyl group, an alkoxy group, a hydroxyl group, a hydroxyalkyl group, a haloalkoxy group, a deuterated alkyl group, a deuterated alkoxy group, a cyano group, an amino group, a nitro group, a carboxyl group, an aldehyde group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R″ is H, an alkyl group, or a cycloalkyl group; R''' is an alkylene group Z is O or S
2. The halogen atoms contained in the halogen, haloalkyl group, and haloalkoxy group are each independently selected from F, Cl, Br, or I; The alkyl groups contained in the amino groups substituted with the alkyl group, deuterated alkyl group, deuterated alkoxy group, hydroxyalkyl group, haloalkyl group, haloalkoxy group, alkoxy group, monoalkyl group or dialkyl group are each independently selected from the group consisting of 1 -C 10 is a linear or branched alkyl group, The alkylene groups each independently represent 1 -C 10 is a linear or branched alkylene group of the formula The cycloalkyl group is 3 -C 10 is a monocyclic or bicyclic cycloalkyl group, The heterocyclyl group is a 3- to 10-membered non-aromatic heterocycle having 1, 2 or 3 heteroatoms selected from N, O and S on the ring; the aryl group is a 6- to 10-membered aryl; the arylene group is a 6- to 10-membered arylene group, The heteroaryl group may be a 5- to 10-membered heteroaromatic ring having 1 to 3 heteroatoms selected from N, O, and S on the ring, or a 5- to 10-membered heteroaromatic ring having 1 to 2 heteroatoms selected from N, O, and S on the ring; the heteroarylene group is a 5- to 10-membered ylidene heteroaromatic ring having 1 to 3 heteroatoms selected from N, O, and S on the ring; The compound represented by formula (I) may be in the form of a tautomer, meso isomer, racemate, diastereoisomer, enantioisomer, or mixture of these isomers.
2. The compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof.
3. The alkyl groups contained in the "alkyl group", "deuterated alkyl group", "deuterated alkoxy group", "hydroxyalkyl group", "haloalkyl group", "haloalkoxy group", "alkoxy group", and "amino group substituted with monoalkyl group or dialkyl group" each independently represent C 1 -C 7 3. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to claim 1 or 2, characterized in that the alkyl group is a straight or branched chain alkyl group.
4. The alkyl groups contained in the "alkyl group", "deuterated alkyl group", "deuterated alkoxy group", "hydroxyalkyl group", "haloalkyl group", "haloalkoxy group", "alkoxy group", and "amino group substituted with a monoalkyl group or a dialkyl group" each independently represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-butyl group, an s-butyl group, an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, an isopentyl group, a 1-ethylpropyl group, a neopentyl group, an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylbutyl group, an isopentyl group, a 1-ethylpropyl group, a neopentyl group, an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylbutyl group, a 2-methylpentyl ...
4. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that the compound is a 2-methylhexyl group, a 3-methylpentyl group, an isohexyl group, a 1,1-dimethylbutyl group, a 2,2-dimethylbutyl group, a 3,3-dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2,3-dimethylbutyl group, a 2-ethylbutyl group, an n-heptyl group, a 2-methylhexyl group, a 3-methylhexyl group, a 2,2-dimethylpentyl group, a 3,3-dimethylpentyl group, a 2,3-dimethylpentyl group, a 2,4-dimethylpentyl group, a 3-ethylpentyl group, or a 2,2,3-trimethylbutyl group.
5. The "alkylene group" is 1 -C 7 5. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 4, which is a straight-chain or branched-chain alkylene group.
6. The "alkylene group" includes a methylene group, an ethylene group, an n-propylene group, an isopropylene group, an n-butylene group, an isobutylene group, a t-butylene group, an s-butylene group, an n-pentylene group, a 1-methylbutylene group, a 2-methylbutylene group, a 3-methylbutylene group, an isopentylene group, a 1-ethylpropylene group, a neopentylene group, an n-hexylene group, a 1-methylpentylene group, a 2-methylpentylene group, a 3-methylpentylene group, an isohexylene group, a 1,1-dimethylbutylene group, a 2,2-dimethylbutylene group, a 3,3-dimethyl The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that the aryl group is selected from the group consisting of butylene, 1,2-dimethylbutylene, 1,3-dimethylbutylene, 2,3-dimethylbutylene, 2-ethylbutylene, n-heptylene, 2-methylhexylene, 3-methylhexylene, 2,2-dimethylpentylene, 3,3-dimethylpentylene, 2,3-dimethylpentylene, 2,4-dimethylpentylene, 3-ethylpentylene, and 2,2,3-trimethylbutylene.
7. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 6, wherein the "cycloalkyl group" is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, or a cycloheptyl group.
8. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 7, wherein the "heterocyclyl group" is a 3- to 10-membered non-aromatic heterocycle having 1 or 2 heteroatoms selected from N and O on the ring.
9. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 8, wherein the "aryl group" is a phenyl group or a naphthyl group.
10. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 9, wherein the "aryl group" is a phenyl group, a 1-naphthyl group, or a 2-naphthyl group.
11. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 10, wherein the "arylene group" is a phenylene group or a naphthylene group.
12. The "heteroaryl group" includes a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, a pyridazin-3-yl group, a pyridazin-4-yl group, a pyrimidin-2-yl group, a pyrimidin-4-yl group, a pyrimidin-5-yl group, a pyrazin-2-yl group, a pyrazin-3-yl group, an indolyl group, an isoindolyl group, an indazolyl group, an indolizinyl group, a purinyl group, a quinolizidinyl group, a quinolyl group, an isoquinolyl group, a cinnolyl group, a phthalazinyl group, a naphthyridinyl group, a quinazolyl group, a quinoxalyl group, a pyridyl group, a thieno[2,3-b]furyl group, a furo[3,2-b]-pyranyl group, a pyrido[2,3-d]oxazinyl group, a pyrazolo[4,3-d]oxazolyl group, an imidazo[4,5-d]thiazolyl group, a pyrazino[2,3-d]pyridazinyl group, an imidazo[2,1-b]thiazolyl group, an imidazo[1,2-b][1,2,4]triazinyl group, a benzothienyl group, a benzoxazolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzooxygenyl group, a benzoxazinyl group, a benzofuryl group, a benzoto riazolyl group, pyrrolo[2,3-b]pyridyl group, pyrrolo[3,2-c]pyridyl group, pyrrolo[3,2-b]pyridyl group, imidazo[4,5-b]pyridyl group, imidazo[4,5-c]pyridyl group, pyrazolo[4,3-d]pyridyl group, pyrazolo[4,3-c]pyridyl group, pyrazolo[3,4-c]pyridyl group, pyrazolo[3,4-d]pyridyl group, pyrazolo[3,4-b]pyridyl group, imidazo[1,2-a]pyridyl group, pyrazolo[1,5-a]pyridyl group, pyrrolo[1,2-b]pyridazinyl group, imidazo[1,2-b]pyridyl group, pyrazolo[1,5-a]pyridyl group, pyrrolo[1,2-b]pyridazinyl group, The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 11, characterized in that the pyrimidinyl group is selected from the group consisting of dazo[1,2-c]pyrimidyl, pyrido[3,2-d]pyrimidyl, pyrido[4,3-d]pyrimidyl, pyrido[3,4-d]pyrimidyl, pyrido[2,3-d]pyrimidyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidyl, pyrazolo[2,3-b]pyrazinyl, and pyrimido[4,5-d]pyrimidyl.
13. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 12, wherein the "heteroarylene group" is a 5-10 membered ylidene heteroaromatic ring having 1 or 2 heteroatoms selected from N, O and S on the ring.
14. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 13, wherein the ylidene heteroaromatic ring of the "heteroarylene group" is selected from a pyridylidene ring, a pyrrolidylidene ring, a pyrazodylidene ring, a pyrimidylidene ring, a pyrazylidene ring, a pyridazylidene ring, a thienylidene ring, or a frylidene ring.
15. n 1 is 1, and n 2 is 1, and n 3 is 1, R 1 , R 2 each independently represents -H, fluorine, chlorine, bromine, iodine, hydroxyl group, hydroxyalkyl group, cyano group, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, s-butyl group, n-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 3-methylbutyl group, isopentyl group, 1-ethylpropyl group, neopentyl group, n-hexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, isopentyl group, n-Heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylbutyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, 2,2,3-trimethylbutyl group, -CD 3 , -C 2 D 5 , -C 3 D 7 , -OCD 3 , -OC 2 D 5 , -OC 3 D 7 , -CF 3 , -CHF 2 , -CH 2 F, -C 2 F 5 , -C 3 F 7 , C 1 -C 7 Haloalkoxy group, C 1 -C 7 selected from an alkoxy group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group; X 1 , X 2 are each independently 1 -C 7 an alkylene group, —O—, —S—, or —NR′—; R' is -H, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-butyl group, an s-butyl group, an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, an isopentyl group, a 1-ethylpropyl group, a neopentyl group, an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylpentyl group, an isohexyl group, a 1,1-dimethylbutyl group, a 2 , 2-dimethylbutyl group, 3,3-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, 2,2,3-trimethylbutyl group, -CD 3 , -C 2 D 5 , -C 3 D 7 , cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; Ar is a phenylene group or a pyridylene group, and a hydrogen atom in the phenylene group or the pyridylene group may be substituted with one, two or three substituents, each of which is independently selected from F, Cl, Br, I, -CN, -Me, and -CF. 3 , -CHF 2 , -C 2 H 5 , -C 3 H 7 , cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, -CD 3 , -OCD 3 , -OMe, -OCF 3 , or -OCHF 2 is selected from Y is -H, -F, -Cl, -Br, -I, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or -CD 3 , -OCD 3 , -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -OCF 3 , -OCHF 2 , -OCH 2 F, cyclopropyl group, -cyclobutyl group, -cyclopentyl group, cyclohexyl group, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 or -OAr', Ar' is selected from a phenyl group, a pyridyl group, a pyrimidyl group, a thienyl group, a pyrrolyl group, a pyrazolyl group, and a quinolyl group, and hydrogen atoms in the ring of the phenyl group, the pyridyl group, the pyrimidyl group, the thienyl group, the pyrrolyl group, the pyrazolyl group, and the quinolyl group may each be independently replaced by 1, 2 or 3 substituents, and each of the substituents is independently selected from F, Cl, Br, -CN, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, s-butyl group, n-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 3-methylbutyl group, isopentyl group, 1-ethylpropyl group, neopentyl group, n-hexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 2,2-dimethylpentyl group, 3,3-dimethylpentyl group, 2,3-dimethylpentyl group, 2,4-dimethylpentyl group, 3-ethylpentyl group, 2,2,3-trimethylbutyl group, -CD 3 , -OCD 3 , C 1 -C 6 Haloalkyl group, -OCH 3 , -OC 2 H 7 , -OC 3 H 7 , C 1 -C 6 selected from haloalkoxy, hydroxyl, hydroxyalkyl, cyano, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups; Z is O or S; 15. A compound of formula (I) according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof.
16. R 1 is -H, and R 2 The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to claim 15, wherein is -H.
17. X 1 is -CH 2 16. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to claim 15, characterized in that it is -, an ethylene group, an n-propylene group, an isopropylene group, an n-butylene group, an isobutylene group, -O-, or -S-.
18. X 1 is -CH 2 - or -O-, and X 2 The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to claim 15, wherein is -O-.
19. 16. The compound of formula (I) according to claim 15, wherein Ar is a phenylene group, a hydrogen atom in said phenylene group may be substituted with one or two substituents, and said substituents are F. or a pharma- ceutically acceptable salt thereof.
20. Y is H, halogen, or -OAr', where Ar' is selected from the group consisting of phenyl, pyridin-3-yl, pyridin-4-yl, and pyrimidin-5-yl, and Ar' is optionally substituted with one or two substituents, such as F, Cl, -CH 3 , -CF 3 Or -OCF 3 16. The compound of formula (I) according to claim 15, wherein the compound is selected from the group consisting of:
21. The compound of formula (I) according to any one of claims 1 to 20, wherein the compound of formula (I) is selected from the following compounds or a pharma- ceutically acceptable salt thereof: 【Chemistry 2A】 【Chemistry 2B】
22. The pharma- ceutically acceptable salts include alkali metal salts, alkaline earth metal salts, or ammonium salts of the compounds of formula (I), the alkali metals including sodium, potassium, lithium, or cesium, and the alkaline earth metals including magnesium, calcium, or strontium; Alternatively, the pharma- ceutically acceptable salt comprises a salt formed between a compound of formula (I) and an organic base, The organic base may comprise a trialkylamine, pyridine, quinoline, piperidine, imidazole, methylpyridine, dimethylaminopyridine, dimethylaniline, N-alkylmorpholine, 1,5-diazabicyclo[4.3.0]nonene-5, 1,8-diazabicyclo[5.4.0]undecene-7, 1,4-diazabicyclo[2.2.2]octane, wherein the trialkylamine comprises trimethylamine, triethylamine, or N-ethyldiisopropylamine, and the N-alkylmorpholine comprises N-methylmorpholine; Alternatively, the pharma- ceutically acceptable salt comprises a salt formed between a compound of formula (I) and an acid, 22. The compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 21, characterized in that the acid comprises an inorganic acid or an organic acid, the inorganic acid comprising hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, or carbonic acid, and the organic acid comprising formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, glutamic acid, or pamoic acid.
23. A method for preparing a compound of formula (I) or a pharma- ceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III) to produce a compound of formula (I), 【Chemistry 3】 The process comprises reacting a compound of formula (IV) with phosphorus oxychloride to produce a compound of formula (II): 【Chemistry 4】 The method includes a step of cyclizing a compound of formula (V) to produce a compound of formula (IV), 【Chemistry 5】 The production method includes a step of reacting a compound of formula (VII) with a compound of formula (VIII) to produce a compound of formula (VI), and further removing a protecting group from the compound of formula (VI) to produce a compound of formula (V), 【Chemistry 6】 The method includes the following reaction route: 【Chemistry 7】 In each formula, n 1 , n 2 , n 3 , R 1 , R 2 , X 1 , X 2 23. A process for preparing a compound of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 22, wherein the definitions of Z, Ar and Y are as defined in any one of claims 1 to 22.
24. A pharmaceutical composition comprising a therapeutically effective dose of one or more compounds of formula (I) or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 22, and optionally pharma- ceutically acceptable auxiliaries.
25. The dosage form of the pharmaceutical composition includes an oral formulation, a rectal formulation, or a parenteral formulation; The oral formulation comprises a solid formulation or a liquid formulation; The solid formulation comprises a tablet, a powder, a granule, or a capsule; The liquid formulations include aqueous or oily suspensions, or syrups; 25. The pharmaceutical composition of claim 24, wherein the formulation for parenteral administration comprises an injectable solution or an aqueous or oily suspension.
26. Use of a compound of formula (I) according to any one of claims 1 to 22 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24 or 25, for the manufacture of an Lp-PLA2 inhibitor.
27. Use of the compound of formula (I) according to any one of claims 1 to 22 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claim 24 or 25, for the manufacture of a medicament for treating a neurodegeneration-related disease, comprising: The neurodegeneration-related disease includes Alzheimer's disease (AD), glaucoma, and age-related macular degeneration (AMD).
28. Use of a compound of formula (I) according to any one of claims 1 to 22 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24 or 25, for the manufacture of a medicament for treating cardiovascular disease, diabetic macular edema (DME), or prostate disease, comprising: The cardiovascular disease comprises atherosclerosis.
Citation Information
Patent Citations
Bicyclic pyrimidone compounds
JP2014521625A
Compound
JP2017520613A
compound
JP2017521456A
